Acceleron Pharma Inc. Stock News

Merck stock jumped Monday after a drug its acquired for billions scored a "must-win" in patients with a rare blood pressure condition. The post Merck Scores A 'Must-Win' For Its $11.5 Billion Accelero

Merck (MRK) revealed that it has completed the acquisition of Acceleron Pharma Inc. (XLRN) through its subsidiary Astros Merger Sub, Inc. The post Merck Completes Acquisition of Acceleron Pharma appeared first on Smarter Analyst .

Here are the five best biotech ETFs to invest in right now.

Sphinx Trading LP bought a new stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 700 shares of the biopharmaceutical companys stock, valued at approximately $120,000. Several other large investors also recently added to or reduced []

The company's financial results are rebounding from their pandemic lows.

Acceleron Pharma (NASDAQ:XLRN) and Brickell Biotech (NASDAQ:BBI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Insider and Institutional Ownership 90.4% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 14.2% []

Fulton Bank N.A. bought a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,507 shares of the biopharmaceutical companys stock, valued at approximately $260,000. Other institutional investors and hedge funds have also recently made changes to []

In the latest trading session, 3.34 million Acceleron Pharma Inc. (NASDAQ:XLRN) shares changed hands as the companys beta touched 0.11. With the companys most recent per share price at $179.81 changing hands around $5.83 or 3.35% at last look, the market valuation stands at $10.64B. XLRNs current price is a discount, trading about -5.66% off Acceleron Pharma Inc. (NASDAQ: XLRN): Dont Ditch XLRN Stock In 2021 Read More »

Acceleron Pharma Inc. (NASDAQ:XLRN) was the target of some unusual options trading on Wednesday. Investors acquired 14,539 call options on the company. This is an increase of 589% compared to the average volume of 2,110 call options. In other news, SVP Adam M. Veness sold 6,650 shares of the firms stock in a transaction that []

Related Stocks: KSU , HYG , XLRN , GAB , TWND , HHLA , SWSS , KINZ , WLTW , ALXN , WORK , SPYV , GRUB , AJRD ,

Invesco Ltd. cut its holdings in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) by 24.3% in the 2nd quarter, Holdings Channel reports. The fund owned 461,416 shares of the biopharmaceutical companys stock after selling 147,763 shares during the period. Invesco Ltd.s holdings in Acceleron Pharma were worth $57,903,000 as of its most recent SEC filing. A []

Related Stocks: XLRN , APLS , FOLD , PMVP , RNA , AADI , KYMR , DICE , BIIB , NUVL , TNGX , CNST , RLMD , OLMA , CNTA , BCTG , ADAP ,